+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
In-Vitro Toxicology Testing Market - Global Forecast 2026-2032- Product Image
In-Vitro Toxicology Testing Market - Global Forecast 2026-2032- Product Image
Sale

In-Vitro Toxicology Testing Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5532927
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The In-Vitro Toxicology Testing Market is projected to reach USD 16.21 Billion in 2026. It is expected to continue growing at a CAGR of 11.52%, reaching USD 31.73 Billion by 2032.

In-vitro toxicology testing is moving from a supporting research tool to a core decision-making platform for pharmaceutical, biotechnology, chemical, cosmetic, food ingredient, and medical device developers. The market is being shaped by validated toxicology assays, human-relevant cell models, 3D cell culture, organ-on-chip systems, high-throughput screening, and computational toxicology that reduce reliance on animal testing while improving early safety prediction.

Regulatory momentum is a central growth driver. The FDA Modernization Act 2.0 removed the statutory requirement for animal testing before human drug trials in the United States, while the European Union has enforced a full cosmetics animal testing ban since 2013 and continues to support the 3Rs principles under Directive 2010/63/EU. OECD test guidelines for skin corrosion, skin irritation, serious eye damage, eye irritation, phototoxicity, genotoxicity, and endocrine activity provide a recognized foundation for broader adoption of non-animal methods and new approach methodologies.

Transformative Shifts in the Testing Landscape

The in-vitro toxicology testing landscape is being transformed by the convergence of regulatory acceptance, ethical expectations, and scientific advances in human biology-based models. Conventional monolayer cell assays remain widely used for cytotoxicity and genotoxicity screening, but demand is accelerating for 3D spheroids, co-culture models, induced pluripotent stem cell-derived tissues, microphysiological systems, and organ-on-chip platforms that better replicate human tissue architecture, metabolism, and exposure dynamics.

End users are also changing how toxicology evidence is generated. Pharmaceutical companies are integrating in-vitro toxicology earlier in discovery to de-risk lead candidates, chemical manufacturers are using integrated approaches to testing and assessment under REACH and OECD frameworks, and cosmetics companies are relying on validated in-vitro methods because animal testing for finished cosmetic products and ingredients is prohibited in the EU. The shift favors providers that combine biological relevance, regulatory documentation, reproducibility, endpoint sensitivity, and scalable assay automation.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasing the value of in-vitro toxicology testing by connecting assay outputs with predictive models, chemical structure data, omics datasets, adverse outcome pathways, and exposure information. Machine learning supports image-based toxicity scoring, high-content screening, quantitative structure-activity relationship modeling, dose-response prediction, and prioritization of compounds for confirmatory testing. These applications are especially valuable when screening large chemical libraries, detecting subtle cellular phenotypes, or identifying mechanisms of toxicity.

The cumulative impact of AI is not the replacement of laboratory science but the creation of more efficient, transparent, and evidence-rich toxicology workflows. Leading organizations are combining AI with good laboratory practice, data provenance, model validation, and explainability requirements. Regulatory relevance depends on traceable datasets, defined applicability domains, reproducible algorithms, bias control, and alignment with OECD principles for validated computational models.

Key Regional Insights

Asia-Pacific is becoming a major hub for in-vitro toxicology testing as China, India, Japan, South Korea, Singapore, and Australia invest in biopharmaceutical R&D, contract research, cosmetics safety, advanced cell models, and regulatory science. North America remains a leading innovation center due to the presence of the FDA, NIH, EPA, established CRO networks, high biopharma research activity, and active programs such as Tox21 that demonstrate the use of high-throughput in-vitro screening for chemical safety prioritization.

Europe continues to set the global benchmark for non-animal testing through EU cosmetics restrictions, REACH requirements, ECHA guidance, OECD-aligned validation practices, and long-standing policy support for the 3Rs. Latin America is expanding adoption through pharmaceutical manufacturing, cosmetics demand, food safety testing, and regulatory modernization led by Brazil and Mexico. The Middle East is building demand through healthcare diversification, national biotechnology strategies, and research infrastructure, while Africa is at an earlier adoption stage but shows long-term potential as laboratory capacity, public health testing, and academic-industry collaboration expand.

Key Group Insights

ASEAN markets are increasingly relevant for in-vitro toxicology testing because Singapore anchors biomedical innovation while Malaysia, Thailand, Indonesia, Vietnam, and the Philippines expand pharmaceutical, food, and cosmetic production. The GCC is gaining visibility as Saudi Arabia, the UAE, and neighboring economies invest in life sciences, health security, clinical research infrastructure, and quality systems. The European Union remains the most influential regulatory group for alternative toxicology methods due to harmonized chemicals and cosmetics rules, REACH implementation, and strong 3Rs policy.

BRICS countries represent scale, manufacturing depth, and growing domestic demand, with China and India particularly important for drug development services, chemical safety testing, and biopharmaceutical research. G7 economies lead in regulatory science, advanced biomanufacturing, biomedical funding, and policy support for new approach methodologies. NATO is not a commercial regulatory bloc, but member alignment on biosecurity, medical countermeasures, and defense health research can indirectly support validated toxicology platforms for emergency preparedness and chemical threat assessment.

Key Country Insights

The United States leads through FDA regulatory modernization, NIH-supported translational science, EPA chemical testing initiatives, and a mature CRO ecosystem. Canada benefits from strong academic toxicology, biotechnology clusters, and alignment with OECD methods, while Mexico is increasingly tied to North American manufacturing, pharmaceuticals, medical devices, and quality testing networks. Brazil is the primary Latin American market due to its pharmaceutical, cosmetics, chemical, and regulatory science activities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine established life science industries with regulatory pressure to reduce animal testing, while Russia maintains demand in pharmaceuticals, chemicals, and public research despite geopolitical constraints. China and India are expanding rapidly through large CRO sectors, domestic drug pipelines, chemical manufacturing, and cosmetics and safety testing requirements. Japan and South Korea emphasize high-quality regulatory science, stem cell research, and advanced cell technologies, and Australia is recognized for biomedical research, clinical development connectivity, and OECD-aligned testing practices.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated assay portfolios that address high-demand endpoints such as cytotoxicity, genotoxicity, skin and eye irritation, hepatotoxicity, cardiotoxicity, immunotoxicity, neurotoxicity, and endocrine disruption. Investments should focus on assays with clear regulatory pathways, defined performance standards, reference chemicals, and documentation packages that can support submissions across OECD, FDA, EPA, EMA, ECHA, and national authority expectations.

Companies should build integrated testing strategies that combine in-vitro assays, in-silico models, exposure science, adverse outcome pathways, and targeted in-vivo testing only where required. Strategic partnerships with CROs, organ-on-chip developers, automation suppliers, biobanks, and AI analytics providers can shorten validation timelines. Leaders should also implement data governance, FAIR data principles, quality management systems, and explainable AI controls to ensure scientific credibility and regulatory confidence.

Research Methodology

The research methodology combines secondary research from regulatory bodies, standards organizations, peer-reviewed literature, patent trends, industry association materials, and publicly available institutional sources. Core sources include OECD test guidelines, FDA and EPA policy documents, European Commission and ECHA guidance, NIH and Tox21 publications, ISO quality standards, PubMed-indexed toxicology studies, and recognized scientific publications on new approach methodologies.

Market interpretation is developed through triangulation across technology adoption signals, regulatory milestones, end-user demand patterns, regional life science infrastructure, laboratory capability, and expert assessment of validated test methods. The analysis avoids unsupported market-size claims and focuses on verifiable indicators, including policy changes, recognized test guidelines, quality standards, documented assay validation, and scientific adoption of new approach methodologies.

Conclusion

In-vitro toxicology testing is positioned for sustained expansion as regulators, companies, and consumers demand safer, faster, and more human-relevant toxicity assessment. The strongest opportunities are emerging where validated assays, advanced cell models, automation, high-content imaging, and AI-enabled analytics are integrated into reproducible and regulator-ready workflows.

Competitive advantage will depend on scientific validation, data integrity, multi-region compliance expertise, and the ability to translate complex biological outputs into actionable safety decisions. Organizations that invest now in scalable, human-relevant, and evidence-based in-vitro toxicology platforms will be better prepared for the next phase of non-animal testing, new approach methodologies, and precision safety assessment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. In-Vitro Toxicology Testing Market, by Service Type
7.1. Introduction
7.2. Biochemical Assays
7.3. Cell Culture Assays
7.3.1. Cell Line Assays
7.3.2. Primary Cell Assays
7.4. Computational Models
8. In-Vitro Toxicology Testing Market, by Technology
8.1. Introduction
8.2. High Throughput Screening
8.2.1. Assay Based
8.2.2. Imaging Based
8.3. Microfluidics
8.4. Organ On Chip
8.5. Three Dimensional Culture
9. In-Vitro Toxicology Testing Market, by Application
9.1. Introduction
9.2. Cosmetics Testing
9.2.1. Ocular Irritation
9.2.2. Skin Irritation
9.3. Drug Discovery
9.3.1. Lead Optimization
9.3.2. Target Validation
9.4. Safety Assessment
9.4.1. Carcinogenicity
9.4.2. Cytotoxicity
9.4.3. Genotoxicity
10. In-Vitro Toxicology Testing Market, by End User
10.1. Introduction
10.2. Academic And Research Institutes
10.3. Contract Research Organizations
10.4. Pharma And Biotech
11. In-Vitro Toxicology Testing Market, by Region
11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa
12. In-Vitro Toxicology Testing Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. In-Vitro Toxicology Testing Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbott Laboratories
15.2. Agilent Technologies, Inc.
15.3. Becton, Dickinson and Company
15.4. Bio-Rad Laboratories, Inc.
15.5. Bio-Techne Corporation
15.6. BioIVT LLC
15.7. Charles River Laboratories International, Inc.
15.8. Creative Bioarray
15.9. ERBC Group
15.10. Eurofins Scientific SE
15.11. Evotec SE
15.12. F. Hoffmann-La Roche AG
15.13. Gentronix Limited
15.14. HD Biosciences Co., Ltd.
15.15. INDIGO Biosciences, Inc.
15.16. Inotiv, Inc.
15.17. InSphero AG
15.18. Intertek Group PLC
15.19. Laboratory Corporation of America Holdings
15.20. LAUS GmbH
15.21. LGC Limited
15.22. Merck KGaA
15.23. Microbac Laboratories Inc.
15.24. Oroxcell
15.25. Promega Corporation
15.26. Qiagen N.V.
15.27. SGS SA
15.28. Thermo Fisher Scientific Inc.
15.29. Toxys, Inc.
15.30. Vimta Labs Ltd.
15.31. WuXi AppTec
List of Figures
FIGURE 1. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BIOCHEMICAL ASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CELL CULTURE ASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CELL CULTURE ASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CELL CULTURE ASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CELL LINE ASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CELL LINE ASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CELL LINE ASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL PRIMARY CELL ASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PRIMARY CELL ASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PRIMARY CELL ASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL COMPUTATIONAL MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL COMPUTATIONAL MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL COMPUTATIONAL MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ASSAY BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ASSAY BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ASSAY BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL IMAGING BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL IMAGING BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL IMAGING BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL MICROFLUIDICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL MICROFLUIDICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL MICROFLUIDICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ORGAN ON CHIP MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ORGAN ON CHIP MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ORGAN ON CHIP MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL THREE DIMENSIONAL CULTURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL THREE DIMENSIONAL CULTURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL THREE DIMENSIONAL CULTURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL COSMETICS TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL COSMETICS TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL COSMETICS TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL OCULAR IRRITATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL OCULAR IRRITATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL OCULAR IRRITATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SKIN IRRITATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SKIN IRRITATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL SKIN IRRITATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL TARGET VALIDATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL TARGET VALIDATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL TARGET VALIDATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SAFETY ASSESSMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SAFETY ASSESSMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SAFETY ASSESSMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL CARCINOGENICITY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CARCINOGENICITY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL CARCINOGENICITY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CYTOTOXICITY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CYTOTOXICITY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CYTOTOXICITY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL GENOTOXICITY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL GENOTOXICITY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GENOTOXICITY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PHARMA AND BIOTECH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PHARMA AND BIOTECH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PHARMA AND BIOTECH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 90. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 93. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 100. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 102. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 103. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 104. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 105. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 110. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 112. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 113. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 114. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 115. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 116. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 117. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 118. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 119. EUROPE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 120. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 126. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 127. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 129. MIDDLE EAST IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 130. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 132. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 133. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 134. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 135. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 136. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 137. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 138. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 139. AFRICA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 143. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 144. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 145. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 146. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 147. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 148. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 149. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 150. ASEAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 151. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 153. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 154. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 155. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 156. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 157. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 158. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 159. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 160. GCC IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 171. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 173. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 174. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 175. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 176. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 177. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 178. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 179. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 180. BRICS IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 181. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 183. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 184. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 185. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 186. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 187. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 188. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 189. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 190. G7 IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 193. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 194. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 195. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 196. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 197. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 198. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 199. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 200. NATO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 202. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 203. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 204. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 205. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 206. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 207. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 208. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 209. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 210. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 211. UNITED STATES IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 212. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 213. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 214. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 215. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 216. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 217. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 218. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 219. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 220. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 221. CANADA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 224. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 225. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 226. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 227. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 228. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 229. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 230. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 231. MEXICO IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 233. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 234. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 235. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 236. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 237. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 238. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 239. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 240. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 241. BRAZIL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 242. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 243. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 244. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 245. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 254. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 255. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 256. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 257. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 258. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 259. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 260. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 261. GERMANY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 263. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 264. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 265. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 266. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 267. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 268. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 269. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 270. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 271. FRANCE IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 272. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 273. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 274. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 275. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 276. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 277. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 278. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 279. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 280. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 281. RUSSIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 282. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 284. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 285. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 286. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 287. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 288. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 289. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 290. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 291. ITALY IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 292. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 293. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 294. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 295. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 296. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 297. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 298. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 299. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 300. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 301. SPAIN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 302. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 303. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 304. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 305. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 306. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 307. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 308. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 309. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 310. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 311. CHINA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 312. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 314. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 315. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 316. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 317. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 318. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 319. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 320. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 321. INDIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 322. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 323. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 324. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-2032 (USD MILLION)
TABLE 325. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 326. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY HIGH THROUGHPUT SCREENING, 2017-2032 (USD MILLION)
TABLE 327. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 328. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY COSMETICS TESTING, 2017-2032 (USD MILLION)
TABLE 329. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 330. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SAFETY ASSESSMENT, 2017-2032 (USD MILLION)
TABLE 331. JAPAN IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 332. AUSTRALIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 333. AUSTRALIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 334. AUSTRALIA IN-VITRO TOXICOLOGY TESTING MARKET SIZE, BY CELL CULTURE ASSAYS, 2017-

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • BioIVT LLC
  • Charles River Laboratories International, Inc.
  • Creative Bioarray
  • ERBC Group
  • Eurofins Scientific SE
  • Evotec SE
  • F. Hoffmann-La Roche AG
  • Gentronix Limited
  • HD Biosciences Co., Ltd.
  • INDIGO Biosciences, Inc.
  • Inotiv, Inc.
  • InSphero AG
  • Intertek Group PLC
  • Laboratory Corporation of America Holdings
  • LAUS GmbH
  • LGC Limited
  • Merck KGaA
  • Microbac Laboratories Inc.
  • Oroxcell
  • Promega Corporation
  • Qiagen N.V.
  • SGS SA
  • Thermo Fisher Scientific Inc.
  • Toxys, Inc.
  • Vimta Labs Ltd.
  • WuXi AppTec

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 16.21 Billion
Forecasted Market Value ( USD ) by 2032 $ 31.73 Billion
Compound Annual Growth Rate11.5%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

In Vitro Toxicology Testing - Global Strategic Business Report - Product Image

In Vitro Toxicology Testing - Global Strategic Business Report

  • Report
  • 460 Pages
  • Global
From
In-Vitro Toxicology Testing Market Report 2026 - Product Image

In-Vitro Toxicology Testing Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Toxicology Testing Services - Global Strategic Business Report - Product Image

Toxicology Testing Services - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
In Vitro Toxicology Testing Market by Product, Toxicity Endpoints & Type, Technology, Method, Service, Region, Competition - Global Forecast to 2031 - Product Image

In Vitro Toxicology Testing Market by Product, Toxicity Endpoints & Type, Technology, Method, Service, Region, Competition - Global Forecast to 2031

  • Report
  • 414 Pages
  • Global
From
In Vitro Toxicology Market Size, Share & Growth Analysis Report - Industry Trends, Competitive Landscape, Segment Insights (by Product Type, Application, End-User), and Forecast 2024-2034 - Product Image

In Vitro Toxicology Market Size, Share & Growth Analysis Report - Industry Trends, Competitive Landscape, Segment Insights (by Product Type, Application, End-User), and Forecast 2024-2034

  • Report
  • 160 Pages
  • Global
From

About the In Vitro Toxicology Testing Market

In Vitro Toxicology Testing is a type of diagnostic testing used to assess the potential toxicity of a substance or product. It is used to evaluate the safety of a product or substance before it is released into the environment or used in humans. In Vitro Toxicology Testing is conducted in a laboratory setting, using cell cultures, animal models, and other methods to assess the potential toxicity of a substance or product. The tests are designed to identify potential adverse effects on the environment, humans, and animals. The results of the tests are used to inform decisions about the safety of a product or substance. Some companies in the In Vitro Toxicology Testing market include Charles River Laboratories, Eurofins Scientific, Covance, SGS, and Intertek. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.